5-Amino-1MQ
Also known as: 5-Amino-1-methylquinolinium, NNMT inhibitor
5-Amino-1MQ is a small-molecule NNMT inhibitor commonly grouped with fat-loss peptides in the research community, taken orally and studied preclinically for effects on fat cells and metabolism. It is a research compound, not an approved medicine in Australia.
- Category
- Metabolic / Fat Loss
- Reported half-life
- Not well established in humans
- Common forms
- Oral capsules (research/grey-market), Oral raw powder (research chemical)
- Research status
- Research compound; NOT approved for human use in Australia. Available data is largely preclinical (cell and animal studies), and its safety and effectiveness in humans are not established.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in animal studies to be associated with reduced fat mass
- Reported to influence cellular NAD+ and metabolic signalling by inhibiting NNMT
- Users report appetite and body-composition changes, though human trial data is limited
- Reported in preclinical work to support muscle-related pathways
How it is reported to work
5-Amino-1MQ is reported to inhibit nicotinamide N-methyltransferase (NNMT), an enzyme involved in fat-cell metabolism. By reducing NNMT activity, it is proposed to raise cellular NAD+ and shift energy handling in fat tissue. Technically it is a small-molecule quinolinium salt rather than a peptide, but it is commonly discussed alongside fat-loss peptides. These mechanisms come mainly from laboratory and animal research and should be regarded as preliminary.
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule NNMT inhibitor taken orally that is commonly grouped with fat-loss peptides in the research and biohacking community, even though it is technically not a peptide. It is a research compound and is not an approved medicine in Australia. This page is educational information, not medical advice, and every effect below is a reported claim, not an established fact.
How does 5-Amino-1MQ work?
It is reported to work by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme active in fat cells. Blocking this enzyme is proposed to raise cellular NAD+ and alter how fat tissue handles energy. This is a laboratory- and animal-derived mechanism, so it should be treated as preliminary rather than proven in humans.
What does the research show?
Most available evidence comes from cell and animal studies rather than large human trials.
| Evidence type | Status |
|---|---|
| Laboratory (in vitro) studies | Present |
| Animal studies | Present |
| Large human clinical trials | Limited/absent |
| Australian medicine approval | Not approved |
Because human data is scarce, reported “results” are anecdotal and should not be read as evidence of benefit or safety.
What do people use it for (reported)?
In the community, 5-Amino-1MQ is reported to be used for fat-loss and body-composition goals, and sometimes for muscle-related support. These are reported uses, not validated clinical outcomes, and nothing here is an encouragement to use it.
Is 5-Amino-1MQ safe?
Its safety in humans is not established. There are no large human trials, long-term risks are unknown, and grey-market products cannot be verified for purity or identity by consumers. Reported side effects include mild digestive upset, headaches and changes in energy or appetite. Because raw powder and capsules can vary in concentration and purity, independent testing is often discussed in the research community for compounds like this. Anyone considering metabolic interventions should speak with a qualified healthcare professional. This article explains what 5-Amino-1MQ is; it does not recommend obtaining or using it, and all effects described remain reported claims.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in animal studies to be associated with reduced fat mass
- Reported convenience of oral dosing versus injectable compounds
- Reported to be associated with metabolic and NAD+-related pathways
- Reported interest for body-composition support in research contexts
Common side effects
- Reported mild digestive upset or nausea
- Reported headaches
- Reported changes in energy or appetite
- Reported sleep disturbance in some users
Rare / serious side effects
- Reported reactions to contaminated or mislabelled grey-market powder
- Reported unpredictable effects due to unverified purity and dosing
- Unknown long-term risks given the absence of human trials
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of 5-Amino-1MQ. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported use of high oral doses well above studied ranges in pursuit of faster fat loss
- Reported stacking with stimulants or other fat-loss agents, amplifying side-effect risk
- Reported dosing errors from unverified raw powder of unknown concentration
- Reported prolonged continuous use without any human long-term safety data
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Users typically report gradual appetite or body-composition changes over several weeks of daily oral use, though human data is limited.
First effects
Some report appetite or energy changes in the first weeks
Noticeable change
Reported body-composition changes described over ~4-8 weeks
Clear results
Reported effects over a longer cycle of consistent use
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take 5-Amino-1MQ. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Oral (capsule or powder) |
|---|---|
| Typical reported dose | Reported roughly 50-150 mg per day |
| Frequency | Reported once daily, often in the morning |
| Cycle length | Reported multi-week cycles (e.g. 8-12 weeks) followed by a break |
Reported community use is commonly described as a daily oral dose taken over a multi-week cycle, sometimes followed by a break. These are reported patterns only, not a recommendation, and no human dosing has been validated in clinical trials.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
5-Amino-1MQ is a research compound and is not an approved medicine in Australia. Human safety and efficacy data are lacking, and grey-market products cannot be verified for purity or identity by consumers. This page is educational and is not medical advice. Anyone considering metabolic or weight-related interventions should consult a qualified healthcare professional.